Miyashi Life Science Mberx Tablet
Miyashi Life Science
Product highlights
- This may be beneficial for managing hyperandrogenism, ovulation disorders, polycystic ovary syndrome, and uterine fibroids.
- Addresses polycystic ovary disease (PCOD) and polycystic ovary syndrome (PCOS).
- Treats acne and promotes hair growth.
Overview Miyashi Life Science Mberx Tablet
Miyashi Life Science's Mberx Tablet offers a comprehensive approach to managing Polycystic Ovary Syndrome (PCOS) and its related conditions in women. This scientifically formulated, synergistic blend helps address the multifaceted nature of PCOS. Mberx acts as a supportive treatment for hyperandrogenism, ovulation irregularities, polycystic ovaries, uterine fibroids, breast fibroadenomas, and diabetic mastopathy. Common hyperandrogenic symptoms such as acne, excessive hair growth, hair thinning, infertility, elevated androgen levels, pelvic pain, and insulin resistance may be alleviated.
Primary Ingredients of Miyashi Life Science Mberx Tablet
- 550 milligrams of myo-inositol
- 200 milligrams of berberine
- Seven point five milligrams of piperine.
Major Benefits of Miyashi Life Science Mberx Tablet:
- This medication serves as supplementary treatment for conditions including excessive androgen levels, ovulation disorders, polycystic ovary syndrome, uterine fibroids, breast fibroadenomas, and diabetic mastopathy.
- Consistent use of this medication may aid in the management of polycystic ovary disease.
- This medication aids in the control of acne and hair thinning.
How to Use Miyashi Life Science Mberx Tablet:
Take two tablets daily as a dietary supplement; consume after meals, or follow your doctor's instructions.
Safety Instruction of Miyashi Life Science Mberx Tablet:
- Always check the product label before administration.
- Keep in a cool, dry location, protected from direct sunlight.
- Store where children cannot access.
Rate your recent purchases
Your ratings and reviews help lakhs of people purchase the right product.
Ratings & Reviews
Ratings 0 Reviews



